TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

被引：0
|
作者：
Mariette, X. [1 ]
Curtis, J. [2 ]
Lee, E. [3 ]
Benda, B. [4 ]
Kaplan, I. [5 ]
Soma, K. [5 ]
Kwok, K. [6 ]
Geier, J. [6 ]
Wang, L. [5 ]
Riese, R. [5 ]
机构：
[1] Univ Paris Sud, Hop Bicetre, Paris, France
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Collegeville, PA USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2139
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0147
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [31] Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
    de Vlam, Kurt
    Coates, Laura
    Ogdie, Alexis
    Helliwell, Philip
    van der Heijde, Desiree
    Gladman, Dafna
    Wang, Cunshan
    Wu, Joseph
    Fallon, Lara
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 848 - 848
  • [32] The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Wisniewska, Natalia
    Pilc, Andrzej
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1415 - 1424
  • [33] The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Alicja Mikrut
    Natalia Wiśniewska
    Andrzej Pilc
    Clinical Rheumatology, 2013, 32 : 1415 - 1424
  • [34] Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
    Cutolo, Maurizio
    Meroni, Marianna
    JOURNAL OF INFLAMMATION RESEARCH, 2013, 6 : 129 - 136
  • [35] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: POOLED PHASE 3 ANALYSIS IN AN AUSTRALIAN RHEUMATOID ARTHRITIS STUDY POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 14 - 14
  • [36] Tofacitinib (CP-690,550), an oral Janus Kinase inhibitor: pooled phase 3 analysis in a German rheumatoid arthritis study population
    Schulze-Koops, H.
    Rubbert-Roth, A.
    Behmer, O.
    Kerkmann, U.
    Kwok, K.
    Burkhardt, H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 11 - 11
  • [37] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Curtis, Jeffrey R.
    Wood, Susan P.
    Soma, Koshika
    Nduaka, Chudy I.
    Benda, Birgitta
    Gruben, David
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Zwillich, Samuel H.
    Wang, Lisy
    Riese, Richard J.
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 837 - 852
  • [38] Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
    Lichtenstein, Gary R.
    Rogler, Gerhard
    Ciorba, Matthew A.
    Su, Chinyu
    Chan, Gary
    Pedersen, Ronald D.
    Lawendy, Nervin
    Quirk, Daniel
    Nduaka, Chudy, I
    Thorpe, Andrew J.
    Panes, Julian
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : 816 - 825
  • [39] Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
    Sandborn, William J.
    Ghosh, Subrata
    Panes, Julian
    Vranic, Ivana
    Su, Chinyu
    Rousell, Samantha
    Niezychowski, Wojciech
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (07): : 616 - 624
  • [40] The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential
    Cutolo, Maurizio
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2013, 5 (01) : 3 - 11
12345